Frailty and survival of patients with renal cell carcinoma: A meta-analysis

肾细胞癌患者的虚弱程度与生存率:一项荟萃分析

阅读:2

Abstract

Frailty is a multidimensional syndrome reflecting decreased physiological reserve and increased vulnerability to stressors, which may adversely affect cancer prognosis. However, its impact on survival outcomes in patients with renal cell carcinoma (RCC) remains unclear. This meta-analysis aimed to evaluate the association between frailty and survival in RCC patients. A systematic search of PubMed, Embase, and Web of Science was conducted for longitudinal studies assessing frailty in adults with RCC. Studies using validated frailty assessment tools and reporting overall survival (OS) and/or progression-free survival (PFS) were included. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup and sensitivity analyses were performed to explore heterogeneity. Eight cohort studies involving 15,989 RCC patients were included. Frailty was associated with significantly poorer OS (HR = 1.79, 95% CI: 1.45-2.20; I² = 30%) and PFS (HR = 2.17, 95% CI: 1.54-3.04; I² = 0%). The association between frailty and OS remained robust across sensitivity analyses by excluding one study at a time and was consistent across subgroups stratified by cancer stage, treatment modality, patient age, frailty assessment method, follow-up duration, and analytic model (all p values for subgroup differences > 0.05). Subtype-specific data according to the histologic type of RCC were unavailable, which limits detailed prognostic interpretation. No significant publication bias was detected. Frailty may be significantly associated with poorer survival outcomes in patients with RCC. Incorporating frailty assessment into routine clinical evaluation may aid in prognostication and individualized treatment planning for this patient population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。